Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/hemab-therapeutics-presents-positive-phase-1-results-for-hmb-001-in-glanzmann-thrombasthenia-at-2024-eahad-annual-congress-302057910.html
https://www.prnewswire.com/news-releases/hemab-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-investigating-hmb-001-for-the-treatment-of-glanzmann-thrombasthenia-302010811.html
https://www.prnewswire.com/news-releases/hemab-therapeutics-presents-new-preclinical-research-demonstrating-effects-of-its-bispecific-antibody-hmb-001-in-factor-vii-deficiency-301861297.html
https://www.prnewswire.com/news-releases/hemab-therapeutics-to-present-new-preclinical-data-on-hmb-001-in-factor-vii-deficiency-and-initial-findings-from-glanzmann-thrombasthenia-natural-history-study-at-the-international-society-on-thrombosis-and-haemostasis-isth-2023-301851408.html
https://www.fiercebiotech.com/biotech/135m-fresh-funds-hemab-aims-leapfrog-development-drugs-neglected-blood-disorders
https://endpts.com/rare-blood-disorders-biotech-hemab-raises-135m-begins-trek-into-clinic/
https://www.clinicaltrialsarena.com/news/hemab-trial-antibody-glanzmann/
https://www.prnewswire.com/news-releases/hemab-therapeutics-announces-first-drug-candidate-hmb-001-a-novel-bispecific-antibody-with-potential-for-treatment-of-rare-bleeding-disorders-301475112.html